FibroGen, Inc., recently disclosed potentially groundbreaking results from a Phase 2 clinical trial evaluating the efficacy of the company’s investigational drug FG-3019 in the treatment of idiopathic pulmonary fibrosis (IPF). Data indicated that the monoclonal antibody agent was able to reduce lung fibrosis in a portion of the IPF patients enrolled, to improve overall lung function.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?